Rapid Resolution of Suicidal Ideation After a Single Infusion of an N -Methyl- D -Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Objective Suicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an N-methyl-D-asparate antagonist, has been reported to have antidepressant effects within hours. We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD). Method Thirty-three subjects with DSM-IV-diagnosed MDD received a single open-label infusion of ketamine (0.5 mg/kg) and were rated at baseline and at 40, 80, 120, and 230 minutes postinfusion with the Scale for Suicide Ideation (SSI), the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression Rating Scale, and the Beck Depression Inventory. The study was conducted between October 2006 and January 2009. Results Suicidal ideation scores decreased significantly on the SSI as well as on the suicide subscales of other rating instruments within 40 minutes; these decreases remained significant through the first 4 hours postinfusion (P Conclusions Suicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion. Future studies with ketamine in suicidal ideation are warranted due to the potential impact on public health. Trial registration clinicaltrials.gov Identifier: NCT00088699.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid-acting dissociative agent ketamine, which has shown its efficacy in treating depression, is known to increase BDNF levels (37, 38).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [38]
In the citing paper
“Extensive experience with human patients has established that ketamine exerts rapid, robust antidepressant, antianhedonic, and antisuicidal actions within two hours of administration that are sustained for at least seven days in patients with major depression following a single infusion or intranasal administration [129-133].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [131]
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [151]
In the citing paper
“Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions in treatment-resistant patients.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [7]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Linehan, M. M., Comtois, K. A., Murray, A. M., Brown, M. Z., Gallop, R. J., Heard, H. L., Korslund, K. E., Tutek, D. A., Reynolds, S. K., & Lindenboim, N. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.757 · Cited by 2,025
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,832
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Cognitive Therapy for the Prevention of Suicide Attempts: A Randomized Controlled Trial
Brown, G. K., Ten Have, T., Henriques, G. R., Xie, S. X., Hollander, J. E., & Beck, A. T. (2005) · JAMA · doi:10.1001/jama.294.5.563 · Cited by 1,045
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Cited by
Items 401–500 of 570
Feng, W., Chen, C., Zeng, Y., & Zhang, B. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111152 · Cited by 11
Ketamine in Substance Use Disorder Treatment: A Narrative Review
Famuła, A., Radoszewski, J., Czerwiec, T., Sobiś, J., & Więckiewicz, G. (2024) · ALPHA PSYCHIATRY · doi:10.5152/alphapsychiatry.2024.241522 · Cited by 10
Lamontagne, S. J., Ballard, E. D., & Zarate, C. A. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100450 · Cited by 12
Self-citationTreatment response with ketamine in chronic suicidality: An open label functional connectivity study
Can, A., Hermens, D. F., Mohamed, A. Z., Shan, Z., Dutton, M., Gallay, C. C., Forsyth, G., Jamieson, D., & Lagopoulos, J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.064 · Cited by 11
Viana, G. S. D. B., Xavier, C. C., do Vale, E. M., Lopes, M. J. P., Alves, V. D. J., Costa, R. D. O., & Neves, K. R. T. (2017) · IBRO Reports · doi:10.1016/j.ibror.2017.11.001 · Cited by 12
Wilkowska, A., Szałach, Ł. P., Słupski, J., Wielewicka, A., Czarnota, M., Gałuszko‐Węgielnik, M., Wiglusz, M. S., & Cubała, W. J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00516 · Cited by 10
Ketamine Use for Suicidal Ideation in the General Hospital: Case Report and Short Review
Vulser, H., Vulser, C., RIEUTORD, M., Passeron, A., LEFEBVRE, D., BAUP, E., Seigneurie, A.-S., Thauvin, I., Limosin, F., & Lemogne, C. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000282 · Cited by 9
Zoladz, P. R., Valle, C. R. D., Goodman, C. S., Dodson, J. L., Smith, I. F., Elmouhawesse, K. M., Sparkman, H. R., Naylor, M. M., & Hopson, E. P. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113895 · Cited by 9
Kang, M. J. Y., Kulcar, E., Chandrasena, R. D., Anjum, M.-R., Fairbairn, J., Hawken, E. R., & Vázquez, G. H. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113645 · Cited by 10
Guanosine as a promising target for fast-acting antidepressant responses
Camargo, A., & Rodrigues, A. L. S. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173422 · Cited by 10
Existing and Novel Biological Therapeutics in Suicide Prevention
Griffiths, J. J., Zarate, C. A., & Rasimas, J. J. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021003 · Cited by 9
“Suicidal tendencies and thoughts that are conceptualized as part of these depressive conditions appear to remit just as rapidly as the overall syndrome.(50) This may give a rapid-acting agent such as ketamine an advantage in the acute management of suicide risk Griffiths et al / Am J Prev Med 2014;47(3S2):S195–S203 S2…”
Self-citationHippocampal subfield volumes predict treatment response to oral ketamine in people with suicidality
Dutton, M., Boyes, A., Can, A., Mohamed, A. Z., Hajishafiee, M., Shan, Z., Lagopoulos, J., & Hermens, D. F. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.11.040 · Cited by 10
Plasma membrane Ca2+-ATPase is a novel target for ketamine action
Boczek, T., Lisek, M., Ferenc, B., & Żylińska, L. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.037 · Cited by 9
Five potential therapeutic agents as antidepressants: a brief review and future directions
Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1071192 · Cited by 10
“This effect was replicated and extended in other open-label or randomized placebo-controlled studies illustrating ketamine’s rapid antidepressant effects in treatment-resistant depression [97], depression with suicidal ideation [98] and treatment-resistance bipolar depression [99].”
ResultAligeti, S., Quinones, M. P., & Salazar, R. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000146 · Cited by 9
Ketamine Modulates Zic5 Expression via the Notch Signaling Pathway in Neural Crest Induction
Shi, Y., Li, J., Chen, C., Xia, Y., Li, Y., Zhang, P., Xu, Y., Li, T., Zhou, W., & Song, W. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00009 · Cited by 9
“Lately ketamine has attracted extensive attention for its quick and significant alleviation of depression (DiazGranados et al., 2010; Frontiers in Molecular Neuroscience | www.frontiersin.org 9 February 2018 | Volume 11 | Article 9 Li et al., 2011).”
BackgroundBDNF Genetic Variant and Its Genotypic Fluctuation in Major Depressive Disorder
Fratelli, C. F., Siqueira, J. W. S., Gontijo, B. R., dos Santos, M. L., Silva, C. M. D. S., & da Silva, I. C. R. (2021) · Behavioural Neurology · doi:10.1155/2021/7117613 · Cited by 10
Shivanekar, S., Gopalan, P., Pizon, A., Spotts, C., Cruz, N., Lightfoot, M., Rohac, R., Baumeister, A., Griffo, A., Panny, B., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192113792 · Cited by 8
Depression Viewed as a GABA/Glutamate Imbalance in the Central Nervous System
Joanna, M. W., Pałucha-Poniewiera, A., Nowak, G., & Pilc, A. (2012) · InTech eBooks · doi:10.5772/31450 · Cited by 8
New perspectives on glutamate receptor antagonists as antidepressants
Chung, C. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0400-8 · Cited by 9
Zhang, M. W., & Ho, R. (2016) · Ethics & Behavior · doi:10.1080/10508422.2016.1189333 · Cited by 8
Electrophysiological phenotypes of suicidality predict prolonged response to oral ketamine treatment
Can, A., Schwenn, P., Isbel, B., Beaudequin, D. A., Bouças, A. P., Dutton, M., Jones, M., Gallay, C. C., Forsyth, G., Bennett, M. R., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110701 · Cited by 8
Jordan, W., Siegel, R., Kumar, R., & Javitt, J. C. (2023) · International Journal of Toxicology · doi:10.1177/10915818231176971 · Cited by 8
Hu, X., Liu, L., Wang, Z., Sun, Y., Li, Z., Zhou, G., Yue, K., Wang, L., Lian, B., Lü, G., et al. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110697 · Cited by 8
Inflammation in Suicidality: Implications for Novel Treatment Options
Janelidze, S., & Brundin, L. (2013) · Modern trends in psychiatry · doi:10.1159/000346085 · Cited by 8
Szabo, S. T., Kilts, J. D., Naylor, J. C., Youssef, N. A., Strauss, J. L., Morey, R. A., Brancu, M., Hamer, R. M., Bradford, D. W., VA Mid-Atlantic MIRECC Work Group, et al. (2014) · Military Medicine · doi:10.7205/milmed-d-13-00337 · Cited by 8
Best, S. R. D. (2015) · Neuropsychiatric Electrophysiology · doi:10.1186/s40810-015-0003-y · Cited by 8
“A parallel line of research has examined the effects of ketamine, an N-methyl-D-aspartate (NMDA) antagonist, on both depression (Berman et al. 2000; Diazgranados et al. 2010; Murrough et al. 2012; Zarate et al. 2006; Zarate et al. 2012; Ibrahim et al. 2012) and OCD (Bloch et al. 2012).”
BackgroundRapid Resolution of Grief with IV Infusion of Ketamine: A Unique Phenomenological Experience
Gowda, M. R., Srinivasa, P., Kumbar, P. S., Vinay, H. R., Muthyalappa, C., & Durgoji, S. (2016) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.175121 · Cited by 9
“Ketamine’s rapid antidepressant effects and usefulness in patients with treatment resistant depression has been proved time and again.[8,9] The mechanisms underlying ketamine’s effects, the simultaneous blockade of NMDA receptors and activation of AMPA receptors, are integral for the induction of the antidepressant re…”
BackgroundSuicide prevention and ketamine: insights from computational modeling
Charlton, C. E., Karvelis, P., McIntyre, R. S., & Diaconescu, A. O. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1214018 · Cited by 7
Animal Models of Risk Factors for Suicidal Ideation and Behaviour
Stuart, S. A., Butler, P., & Robinson, E. S. J. (2014) · Springer eBooks · doi:10.1007/978-3-319-09964-4_18 · Cited by 8
Acero-Castillo, M. C., Correia, M. B. M., Caixeta, F. V., Motta, V., Barros, M., & Maior, R. S. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110088 · Cited by 8
Chen-Li, D. C. J., Mansur, R. B., Vincenzo, J. D. D., Chisamore, N., Kaczmarek, E. S., McIntyre, R. S., & Rosenblat, J. D. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116282 · Cited by 10
La kétamine dans le traitement du trouble dépressif aigu sévère
Brittner, M., Micoulaud‐Franchi, J., Richieri, R. M., Boyer, L., Adida, M., Lançon, C., & Fond, G. B. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2013.11.013 · Cited by 7
“Par ailleurs, deux études récentes de forte puissance (STAR-D et Munich Antidepressant Response Signature Projects) ont mis en évidence une relation entre les idées suicidaires et le polymorphisme des gènes codant pour les récepteurs au glutamate [23].”
BackgroundInfluentialDo we need pharmacogenetics to personalize antidepressant therapy?
Lanni, C., Racchi, M., & Govoni, S. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1237-5 · Cited by 9
Weisler, R. H., McIntyre, R. S., & Bauer, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.846519 · Cited by 8
Purinergic modulation of pathways associated to suicidal behavior
Gonçalves, M. C. B., Corrêa-Velloso, J. C., Naaldijk, Y., Cheffer, A., & Ulrich, H. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0088-3 · Cited by 7
“treatment with the NMDA receptor antagonist ketamine resulted in an improvement against suicidal ideation in patients suffering from major depression [15].”
BackgroundIrwin, M. N., & VandenBerg, A. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.05.200 · Cited by 7
Camargo, A., Dalmagro, A. P., Delanogare, E., Fraga, D. B., Wolin, I. A. V., Zeni, A. L. B., Brocardo, P. S., & Rodrigues, A. L. S. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.12.010 · Cited by 7
The Basic and Clinical Pharmacology of Ketamine
Fourcade, E. W., & Lapidus, K. A. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_2 · Cited by 9
Safety and pharmacokinetics study of inhaled esketamine after a single dose in healthy volunteers
Janowska, S., Tratkiewicz, E., Matłoka, M., Perko, P., Gaciarz, M., Urban, A., & Wieczorek, M. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.793 · Cited by 7
Le, G. H., Wong, S., Johnson, D. E., Lu, A., Orsini, D. K., Chisamore, N., Luch, S. D. D., Rosenblat, J. D., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121081 · Cited by 7
Gillespie, C. F., Szabo, S. T., & Nemeroff, C. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00036-9 · Cited by 7
“Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?”
Soleimani, L., Welch, A. K., & Murrough, J. W. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0065-2 · Cited by 6
[Glutamatergic conception of mood disorders].
Permoda‐Osip, A., & RYBAKOWSKI, J. K. (2011) · PubMed · Cited by 13
Ketamine and Depression: A Review
Ryan, W. C., Marta, C. J., & Koek, R. J. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.40 · Cited by 6
“International Journal of Transpersonal Studies 61 Ketamine for Depression Cornwell, B. R., Salvadore, G., Furey, M., Marquardt, C. A., Brutsche, N. E., Grillon, C., & Zarate, C. A. (2012). Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatmentresistant major depression.”
InfluentialPochwat, B., Domin, H., Rafało-Ulińska, A., Szewczyk, B., & Nowak, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134791 · Cited by 6
Prevalence and perceptions of ketamine use among Danish clubbers: A mixed-method study
Ravn, S., & Demant, J. (2012) · Nordic Studies on Alcohol and Drugs · doi:10.2478/v10199-012-0035-6 · Cited by 9
Gunduz‐Bruce, H., Kenney, J. G., Changlani, S., Peixoto, A. J., Gueorguieva, R. V., Leone, C. A., & Stachenfeld, N. S. (2017) · Experimental Physiology · doi:10.1113/ep086212 · Cited by 6
“…post-mortem (Ongur et al. 1998; Rajkowska et al. 1999; Miguel-Hidalgo et al. 2000, 2002; Cotter et al. 2001; Bowley et al. 2002; Hamidi et al. 2004; Khundakar et al. 2011), imaging (Yuksel & Ongur, 2010) and clinical trials data (Berman et al. 2000; Zarate et al. 2006; DiazGranados et al. 2010).”
BackgroundMethodRawal, B., Rančić, V., & Ballanyi, K. (2022) · Brain Sciences · doi:10.3390/brainsci12050651 · Cited by 6
“For example, the NMDA-type iGluR antagonist ketamine has an acute antidepressant action that can reduce suicide ideation [10,11].”
BackgroundZarate, C. A. (2017) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.08.009 · Cited by 6
Self-citationShadli, S. M., Delany, R. G., Glue, P., & McNaughton, N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.900105 · Cited by 5
Ivanović, A., Petrović, J., Stanić, D., Nedeljković, J., Ilić, M., Jukić, M. M., Pejušković, B., & Pešić, V. (2025) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2025.104006 · Cited by 6
Logerot, S., Baudrant, M., Lehmann, A., Schir, É., Dumolard, A., Alibeu, J., Hodaj, H., & Dominici, C. (2013) · Douleurs Évaluation - Diagnostic - Traitement · doi:10.1016/j.douler.2013.01.006 · Cited by 8
“[24] DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, et al.”
BackgroundLento, R. M., & Boland, H. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-30687-8_11 · Cited by 6
A feasibility study of low‐dose ketamine for acute management of suicidal ideation
Gaither, R., Ranney, M. L., Peachey, A. M., Burock, J., Rogers, J., Bucci, L., & Beaudoin, F. L. (2022) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12790 · Cited by 7
“This study evaluated (1) feasibility of ketamine administration in an ED setting with a high-risk patient population and (2) short-term effectiveness of a 0.”
BackgroundMethodInfluentialChaudhary, P., Shah, P., & Mehta, P. (2022) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_231_21 · Cited by 5
“[5,9,14,15,25] This rapid antidepressant and anti-suicidal effects are in contrast to traditional monoamine-based antidepressants that take weeks to months to exert their full antidepressant effect.”
Making Ketamine Work in the Long Run
Associates, I. P., & Early, T. S. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.141 · Cited by 5
“…inhibitors and tricyclic antidepressants that typically take weeks or months to reach full effectiveness—and too often are not effective at all—ketamine appears to provide rapid relief from symptoms of depression, even in treatmentresistant cases (Zarate et al., 2006; Diazgranados et al., 2010).”
Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies
Averill, L. A., Murrough, J. W., & Abdallah, C. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_7 · Cited by 6
Infusing Hope Into the Treatment of Suicidality: a Review of Ketamine’s Effects on Suicidality
Rengasamy, M. L., Hsiung, K. S., & Price, R. B. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00184-3 · Cited by 5
Ramazi, S., آرانی, ف., Safaei, A., Abbasi, Z., Heidari, Z., Nafchi, H. G., Mohammadsadeghi, H., & Karimzadeh, F. (2021) · The Neuroscience Journal of Shefaye Khatam · doi:10.52547/shefa.9.2.119 · Cited by 5
Mansuri, Z., Shah, B., Yadav, G., Kamil, S. H., Kainth, T., Srinivas, S., Patel, H., Reddy, A., & Bachu, A. K. (2024) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.23lr03607 · Cited by 5
Mora, R., López, S. G., Villar, M., Palmer, R., & Perlado, B. R. (2016) · Psiquiatría Biológica · doi:10.1016/j.psiq.2016.11.002 · Cited by 6
A long, strange trip: Ketamine treatment in psychiatry
Nutt, D. J., Morgan, C. J. A., Erritzøe, D., Greenway, K. T., & Young, A. H. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251379393 · Cited by 5
“Later, the same team also demonstrated that ketamine could reduce suicidal ideation in similar treatment-resistant depression patients (DiazGranados et al., 2010a) as well as lift depressive symptoms, also in patients with bipolar disorder (Diazgranados et al., 2010b; Zarate et al., 2012).”
Dodds, C., Dawson, R. L., Lim, A., Tye, S. J., & Nasrallah, F. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396255 · Cited by 4
Geller, J. A., Keith, K., Smith, C., Pacilio, R. M., Arfken, C. L., Oxley, M., & Mischel, N. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100688 · Cited by 4
RETRACTED–Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study
Mills, N. T., Nikolin, S., Glozier, N., Barton, D., Baune, B. T., Fitzgerald, P. B., Glue, P., Sarma, S., Rodgers, A., Hadzi-Pavlovic, D., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.250 · Cited by 5
RetractedThe Potential Role of the Endogenous Opioid System in the Antidepressant Effect of Ketamine
Shenoda, B. B. (2014) · Research in Neurology An International Journal · doi:10.5171/2014.733320 · Cited by 4
“…dose was found to be effective in TRD (Zarate et al., 2006) and this was followed by many clinical trials showing the remarkable antidepressant effect of ketamine (aan het Rot et al., 2010; DiazGranados et al., 2010; Larkin and Beautrais, 2011; Machado-Vieira et al., 2009b; Mathew et al., 2010).”
BackgroundKetamin als Antidepressivum: Die aktuelle Studienlage
Ritter, P. S., Bauer, M., & Pilhatsch, M. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4132-5 · Cited by 6
Antidepressants and Suicide Risk: Harmful or Useful?
Courtet, P., Nobile, B., & López‐Castromán, J. (2017) · Springer eBooks · doi:10.1007/978-981-10-4816-6_18 · Cited by 10
Liu, H., Wu, X., Chen, J., & Fang, Y. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00794-6 · Cited by 4
“More importantly, ketamine can quickly and effectively reduce suicidal ideation within 40 min after injection, and maintain curative effects for up to one week thereafter [5].”
BackgroundKetamine in treatment-resistant depression
Lapidus, K. A. B., & Mathew, S. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.027 · Cited by 4
[Anatomo-echocardiographic correlation of scimitar syndrome in adults].
Espinola-Zavaleta, N. G., Muñoz‐Castellanos, L., Játiva-Chávez, S., & Zamora-González, C. (2005) · PubMed · Cited by 4
Ketamine as a Rapid-Acting Antidepressant: Promising Clinical and Basic Research
Tuck, A. N., & Ghazali, D. H. (2017) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2017.120302 · Cited by 6
Wu, B., Xu, Y., Xie, Y., Li, Y., Huang, Y. M., Feng, Y., & Zhu, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101251 · Cited by 4
“Administration of Ket induces rapid and sustained antidepressant [5,6] and anti-suicidal effects [7].”
Escarment, J., Wey, P., Martinez, J. Y., & Lohéas, D. (2016) · Journal of Burn Care & Research · doi:10.1097/bcr.0000000000000346 · Cited by 3
Health Economics: The Hidden Costs of Mental Illness
Martini, D. R., & Attallah, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-12665-0_1 · Cited by 3
Inflammation and Suicidal Behavior
Postolache, T. T., Manalai, P., Brenner, L. A., & Brundin, L. (2015) · Advances in biological psychiatry · doi:10.1159/000434746 · Cited by 4
Hilal, F. F., Jeanblanc, J., & Naassïla, M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023028 · Cited by 4
Ketamine/esketamine for treatment-resistant depression
Nikayin, S., & Sanacora, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00013-x · Cited by 6
Quiroz, J. A., Chen, G., Drevets, W. C., Henter, I. D., & Manji, H. K. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.004 · Cited by 5
Self-citationBallard, E. D., & Price, R. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_4 · Cited by 4
Kadriu, B., Yuan, S., Farmer, C., Nugent, A. C., Lener, M. S., Niciu, M. J., Park, M., Yazdian, A., Ballard, E. D., Henn, F. A., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000866 · Cited by 3
Self-citationFalcone, T., Staniskyte, M., Forcén, F. E., & Vengoechea, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-74391-2_1 · Cited by 3
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Assessing suicide risk in chronic pain management: a narrative review across drug classes
Brezić, N., Gligorevic, S., Candido, K. D., & Knežević, N. N. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2391999 · Cited by 2
Translational Neuropsychopharmacology for Major Depression: Targeting Neurotransmitter Systems
Kim, H., Kim, Y., & Jeon, H. J. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_15 · Cited by 2
Janowska, S., Tratkiewicz, E., Matłoka, M., Perko, P., Gaciarz, M., & Wieczorek, M. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.210 · Cited by 2
Moayedi, F., Massoudifar, A., Namazi, S., Zadeh, H. M., Seddigh, S. H., & Teshnizi, S. H. (2022) · Disease and Diagnosis · doi:10.34172/ddj.2023.437 · Cited by 3
Utilization of Ketamine for Major Depression
Dao, R., & Aggarwal, A. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00027 · Cited by 2
Antidepressants: current mechanisms and new hopes
Greener, M. (2014) · Nurse Prescribing · doi:10.12968/npre.2014.12.1.38 · Cited by 2
Treatment of the psychiatric patient
Chepenik, L. G., & Mallory, M. N. S. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139088077.026 · Cited by 2
Ketamine Treatment for Major Depression
Anand, A., Mathew, S. J., & Janicak, P. G. (2011) · Psychopharm Review · doi:10.1097/01.psyphr.0000410133.47951.30 · Cited by 2
S-ketamine for the treatment of depression
Järventausta, K., Kampman, O., Yli‐Hankala, A., & Leinonen, E. V. J. (2015) · Cited by 2
Ketamine-The Confluence of Old and Recent Concepts
Bajwa, S. S., Kaur, G., & Khanna, M. (2017) · Journal of Pain & Relief · doi:10.4172/2167-0846.1000283 · Cited by 3
“5 mg/kg IV has been used as rapid treatment for major depression, bipolar depression resistant to electroconvulsive therapy [14,15].”
MethodOverview of ketamine for major depression: efficacy and effectiveness
Bahji, A., Vázquez, G. H., Brietzke, E. M., & Zarate, C. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00005-8 · Cited by 2
Self-citationElectroconvulsive therapy in treatment resistant depression: What is new?
Kaliora, S. C. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.053 · Cited by 2
Immune System Related Markers: Changes in childhood Neuropsychiatry Disorders Cause and Consequence
Falcone, T., & Franco, K. S. N. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_9 · Cited by 2
Mystical Experience Induced by Esketamine Treatment: A Real-World Observational StudyPreprint
Mallevays, M., Fuet, L., Danon, M., Lodovico, L. D., Jaffré, C., Bouzeghoub, L., Mrad, S. M., Rousselet, A.-V., Allary, L., Müh, C., et al. (2026) · medRxiv · doi:10.64898/2026.03.31.26349757 · Cited by 2
Karanović, J., Beraković, D., Katrašnik, M., Arčan, I. Š., Pantović-Stefanović, M., Radenković, L., Garai, N., Ivković, M., Pavicevic, D. S., Zupanc, T., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01895-9 · Cited by 1
Vieira, F., Caliman‐Fontes, A. T., Souza‐Marques, B., Faria-Guimarães, D., Lins-Silva, D. H., Santos‐Lima, C., Jesus‐Nunes, A. P., & Quarantini, L. C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116443 · Cited by 1
Metadata
- Authors
- DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A.
- Affiliations
- National Institute of Mental Health (US)
- National Institutes of Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-07-13
- Volume
- 71
- Issue
- 12
- Pages
- 1605-1611
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC3012738
- OpenAlex
- W2103255996
- Cited by
- 564
- References
- 41
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 22 · 2023: 21 · 2022: 41 · 2021: 41 · 2020: 39 · 2019: 35 · 2018: 49 · 2017: 33 · 2016: 51 · 2015: 59 · 2014: 52 · 2013: 40 · 2012: 30
- FWCI
- 23.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 MH999999)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- suicidal ideation, ketamine, NMDA receptor antagonists, rapid antidepressant effects, single-dose infusion, hopelessness, anxiety, depression
- MeSH terms
- Adult, Antidepressive Agents, Depression, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Time Factors, N-Methylaspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Diagnostic and Statistical Manual of Mental Disorders, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.